Indinavir 400 mg Capsules

Deciding whether Indinavir capsules fit your regimen

The most useful fact to weigh before comparing Indinavir with other protease inhibitors is the practical demand of its traditional dosing routine. The 400 mg capsules contain indinavir alone and do not include a pharmacokinetic booster. Indinavir has historically been taken at fixed intervals several times a day, although specialists have also used it with a boosting agent in some regimens. This can require more attention to timing, food instructions, fluid intake and storage than many newer treatment options. If you are comparing this product with another antiretroviral medicine, its compatibility with the complete prescribed regimen and your ability to follow the schedule consistently matter more than the age of the medicine alone.

Product identity and place in HIV treatment

Indinavir is the active ingredient in these 400 mg oral capsules. It belongs to the HIV protease inhibitor class and is used for HIV-1 infection in adults as one component of combination antiretroviral therapy, not as treatment on its own. A complete regimen combines medicines that act at different stages of the viral life cycle. Readers exploring how such combinations have been constructed may find it useful to review Combivir, a fixed-dose lamivudine and zidovudine medicine that has been used as part of combination HIV treatment. Our HIV medicines category provides a broader view of available products, but an HIV specialist must decide which agents can be combined safely and effectively.

Indinavir should not be confused with Crixivan, a brand name historically associated with indinavir, or with another protease inhibitor simply because the medicines belong to the same class. The concrete product described here is Indinavir 400 mg in capsule form for oral use. Its strength, formulation and pack size should all match the specialist's instructions.

Who might discuss Indinavir with an HIV specialist?

Indinavir capsules are established for adults with HIV-1 infection as part of combination therapy. However, current treatment choices depend on previous antiretroviral exposure, resistance results, other medicines, organ function and whether the proposed schedule is realistic. These are matters for a specialist consultation rather than self-selection.

• Previous treatment and resistance: a clinician will consider which antiretroviral medicines have already been used, why any earlier regimen was changed and whether resistance testing supports the proposed combination.
• Kidney stone history: indinavir has a recognised association with nephrolithiasis, so previous kidney stones, kidney disease or urinary symptoms require careful review.
• Pregnancy: use during pregnancy requires an individual assessment of potential benefit and risk, including possible changes in indinavir exposure and concerns about bilirubin.
• Diabetes or high blood glucose: protease inhibitors, including indinavir, have been associated with new or worsening hyperglycaemia. Additional monitoring may therefore be needed.
• Other medicines: indinavir has clinically important interactions, and the specialist needs a complete list of prescription medicines, non-prescription products and supplements.
• Daily routine: a multiple-dose schedule is only suitable when doses and any food instructions can be followed reliably every day.

How does Indinavir work in combination therapy?

Indinavir blocks HIV protease, an enzyme the virus uses to cut long protein chains into the functional components needed to form mature viral particles. When protease is inhibited, the particles produced are immature and substantially less able to continue the infection cycle. Indinavir does not remove HIV from the body, and it does not cover every stage of viral replication. This is why it is prescribed with other antiretroviral agents rather than used alone.

Maintaining adequate medicine levels is important. Repeatedly missed or badly delayed doses can allow viral replication to resume and increase the risk that resistance will develop. Resistance may reduce the future effectiveness of indinavir and can sometimes affect related protease inhibitors. The practical value of the medicine therefore depends not only on its mechanism but also on whether the entire prescribed regimen can be taken consistently.

Building a reliable capsule routine

Indinavir has traditionally been prescribed at fixed intervals during the day, so the exact timetable and food instructions need to come from the prescribing HIV service. The schedule may differ if interacting medicines or a boosting agent are involved. Do not infer the number of capsules per dose from the 400 mg capsule strength or the pack quantity.

• Follow the prescribed timing: use reminders or a written schedule if necessary, but do not independently move doses to more convenient times.
• Maintain appropriate fluid intake: adequate hydration is an important part of reducing the risk of indinavir-associated kidney stones. Ask the specialist what is appropriate if a heart, kidney or other condition limits fluid intake.
• Observe food instructions: food can affect indinavir exposure, and the relevant directions depend on the prescribed regimen. Follow the dispensing label and patient leaflet.
• Handle missed doses safely: consult the patient leaflet or prescribing service for regimen-specific advice. Do not take a double dose unless a clinician has expressly instructed you to do so.
• Protect the capsules from moisture: store them at 15°C to 30°C in the original, tightly closed container with the desiccant. Keep the desiccant in the container and do not swallow it.

Seek prompt clinical advice if urinary pain, blood in the urine, severe pain in the side or back, markedly reduced urination or another concerning symptom develops. A routine that looks manageable on paper may still need adjustment if adverse effects or interactions make adherence difficult.

Available strength and pack choices

We offer Indinavir as 400 mg oral capsules, the only strength listed for this product in our catalogue. The available pack quantities are 30 and 60 capsules. These choices do not represent different formulations or release types: both contain the same capsule strength and use the same oral route.

Pack selection should follow the prescribed number of capsules and planned review or refill interval. A larger pack is not inherently more appropriate, and neither pack size determines the dose. Before ordering, check the medicine name, 400 mg strength, capsule form and quantity against the specialist's directions. This is particularly important where a complete regimen contains several antiretroviral medicines with different schedules.

What outcomes can treatment provide, and when are they assessed?

Indinavir helps suppress HIV replication when it is taken consistently as part of an effective combination regimen. The goals are to reduce viral load, preserve or improve immune function and lower the risk of HIV-related illness. It is not a cure, and a person may not feel a noticeable day-to-day effect even when treatment is working.

HIV services assess response principally with viral-load testing and CD4 counts, alongside clinical review and safety monitoring. The timing of tests depends on the treatment plan, previous results and any concerns about adherence, resistance or adverse effects. Viral suppression develops over time rather than immediately after a capsule is taken. A result that is not improving as expected needs specialist assessment; it should not lead to self-directed dose changes or abrupt discontinuation.

Consistency remains important after viral suppression is achieved. Continuing the complete regimen as prescribed helps maintain control, whereas irregular use can allow viral levels to rebound. If the schedule proves impractical, discussing an alternative early is safer than repeatedly missing doses.

Important safety priorities

Indinavir has safety considerations that should be reviewed before treatment and monitored while it is used. The patient leaflet for the supplied medicine and the specialist's instructions remain the primary sources of individual advice.

• Kidney and urinary problems: nephrolithiasis is a well-documented risk. Hydration may reduce that risk, but new urinary symptoms still require clinical assessment.
• Bilirubin and jaundice: indinavir can increase bilirubin. Yellowing of the skin or eyes should be reported, even though bilirubin changes do not always indicate liver injury.
• Blood glucose: new diabetes, worsening diabetes and severe hyperglycaemia have been reported with protease inhibitors. Symptoms such as unusual thirst or frequent urination warrant advice.
• Hypersensitivity: the medicine must not be used by anyone with known hypersensitivity to indinavir or an ingredient in the capsule. Urgent help is needed for signs of a severe allergic reaction.
• Pregnancy and infant feeding: pregnancy requires an individual specialist benefit-risk decision. People with HIV taking this regimen should not breastfeed unless their specialist HIV team has provided a specific, clinically supported infant-feeding plan.
• Children: an established satisfactory paediatric dosing regimen is not available for these capsules, and kidney stones occurred more frequently in studied children. Paediatric use requires specialist assessment.
• Driving and machinery: dizziness and blurred vision can occur. Do not drive or operate machinery if these effects are present.

Serious, persistent or unexpected symptoms should be assessed by a clinician. Suspected adverse reactions can also be reported to the MHRA through the Yellow Card Scheme, but reporting does not replace urgent medical care when it is needed.

Interactions and practical precautions

Indinavir is metabolised through enzyme pathways involved in the handling of many other medicines. Some combinations can raise indinavir exposure and increase adverse effects, while others can lower exposure and make treatment less reliable. St John's wort is a particularly important example because it can reduce concentrations of protease inhibitors and should not be started alongside indinavir without specialist review.

Give the prescriber and dispensing pharmacist a complete, current list of everything you take. Include medicines prescribed by another service, non-prescription painkillers or cold remedies, vitamins, bodybuilding products, recreational substances and herbal preparations. A medicine used only occasionally can still be relevant. Check before starting, stopping or changing any product, because an interaction may require monitoring, a dose adjustment or selection of a different antiretroviral.

Indinavir also needs to remain in its original tightly closed container with the desiccant. Do not transfer the capsules to an ordinary pill organiser for prolonged storage unless a pharmacist has confirmed a suitable way to protect them from moisture. Keep all medicines out of the sight and reach of children.

How does Indinavir compare with other HIV treatment options?

The comparison is conditional rather than a question of one protease inhibitor being universally best. An HIV specialist may consider atazanavir, darunavir, lopinavir/ritonavir, saquinavir, nelfinavir, fosamprenavir or tipranavir according to resistance results, previous treatment, interaction risks, kidney and liver function, adverse-effect history and the other medicines in the proposed regimen. Some alternatives use a boosting agent or support a less frequent schedule, but they introduce their own interaction, monitoring and tolerability considerations.

Kaletra contains lopinavir and ritonavir in a fixed-dose combination, so it is not a direct like-for-like substitute for single-ingredient Indinavir capsules. Darunavir is also commonly used with a boosting agent, while the suitability of atazanavir depends on the complete regimen and individual clinical factors. None should be substituted without specialist review, particularly where previous resistance or treatment failure is relevant.

Is Indinavir available on prescription in the UK?

Indinavir is a prescription-only antiretroviral medicine in the United Kingdom and should be prescribed and monitored through an HIV specialist service. Where clinically indicated, HIV antiretroviral treatment is generally provided through NHS specialist care rather than managed as an ordinary community-pharmacy purchase. This clinical and regulatory position is separate from our catalogue and ordering arrangements.

A catalogue listing for Indinavir 400 mg capsules does not by itself establish that a particular presentation currently has a UK marketing authorisation. The exact product and licence status can be checked in the MHRA medicines register before supply. Do not treat online availability or a displayed pack choice as a substitute for specialist prescribing, interaction checks or ongoing blood monitoring.

Ordering and delivery support

We list Indinavir 400 mg capsules in packs of 30 and 60. Before placing an order, make sure the selected quantity matches the specialist's directions and that the complete regimen has been clinically reviewed. We do not present pack size as a treatment recommendation, and ordering the capsules does not replace care from an HIV service.

AntiInfectiveMeds has supported customers since 2010. Our support team is available 24 hours a day by email, online chat and phone, and a pharmacist is available for medicine-related questions. We can help with questions about the listed pack choices, an order or appropriate storage after delivery. Questions about starting treatment, changing the dose, managing an interaction or replacing another antiretroviral should be directed to the prescribing HIV specialist. No delivery timeframe should be assumed unless it is confirmed during the ordering process.

Decision summary

Indinavir 400 mg capsules remain a potential component of combination antiretroviral therapy, but they require a carefully planned routine and specialist oversight. The main decision factors are previous treatment and resistance, kidney stone risk, interactions, glucose monitoring, the practical dosing schedule and whether another protease inhibitor or antiretroviral class would fit the complete regimen better.

Confirm the exact 400 mg capsule product, prescribed quantity and monitoring plan before choosing between the 30- and 60-capsule packs. If Indinavir is the specialist-selected option, we can provide the listed pack choice and support with ordering and storage questions. Clinical decisions and any change from Indinavir to an alternative such as Kaletra must remain with the HIV specialist service.